Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | July 2015 |
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
This randomized phase III trial studies how well doxorubicin hydrochloride and
cyclophosphamide followed by paclitaxel with or without carboplatin work in treating
patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin
hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and
cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and
carboplatin in treating triple-negative breast cancer.
cyclophosphamide followed by paclitaxel with or without carboplatin work in treating
patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin
hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and
cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and
carboplatin in treating triple-negative breast cancer.
PRIMARY OBJECTIVES:
I. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin (doxorubicin hydrochloride)/cyclophosphamide followed by paclitaxel will improve
the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed
by paclitaxel when administered to patients with operable node-positive or high-risk
node-negative triple-negative breast cancer.
SECONDARY OBJECTIVES:
I. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the overall survival (OS)
compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to
patients with operable node-positive or high-risk node-negative triple-negative breast
cancer.
II. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the breast cancer-free
survival (BCFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when
administered to patients with operable node-positive or high-risk node-negative
triple-negative breast cancer.
III. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the recurrence-free
interval (RFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when
administered to patients with operable node-positive or high-risk node-negative
triple-negative breast cancer.
IV. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the distant recurrence-free
interval (DRFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when
administered to patients with operable node-positive or high-risk node-negative
triple-negative breast cancer.
V. To determine the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel
administered concurrently with carboplatin compared to the toxicity of
doxorubicin/cyclophosphamide followed by paclitaxel alone.
VI. To determine if germline breast cancer (BRCA) status is associated with benefit in IDFS
or OS from the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel in patients with operable node-positive
or high-risk node-negative triple-negative breast cancer.
VII. To determine if the addition of carboplatin will improve the RFI among the homologous
recombination (HR) deficient patients as determined by the homologous recombination
deficiency (HRD) score.
VIII. To determine whether the efficacy of carboplatin on RFI in HR-deficient patients
differs from that in patients who are not HR-deficient.
IX. To collect tissue and blood samples at several occasions for future biomarkers
development in predicting risk of breast cancer recurrence in patients with operable
node-positive or high-risk node-negative triple-negative breast cancer treated with
doxorubicin/cyclophosphamide followed by paclitaxel with or without carboplatin and
predicting benefit from the addition of carboplatin among these patients.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (DOXORUBICIN HYDROCHLORIDE [A] CYCLOPHOSPHAMIDE [C]-->WEEKLY PACLITAXEL [WP]):
Patients receive doxorubicin hydrochloride intravenously (IV) over 15 minutes and
cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses
in the absence of disease progression or unacceptable toxicity. Patients then receive
paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the
absence of disease progression or unacceptable toxicity.
ARM II (AC-->WP + CARBOPLATIN): Patients receive doxorubicin hydrochloride and
cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1,
8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks
for 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 5 years and
then every 12 months for 5 years.
I. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin (doxorubicin hydrochloride)/cyclophosphamide followed by paclitaxel will improve
the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed
by paclitaxel when administered to patients with operable node-positive or high-risk
node-negative triple-negative breast cancer.
SECONDARY OBJECTIVES:
I. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the overall survival (OS)
compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to
patients with operable node-positive or high-risk node-negative triple-negative breast
cancer.
II. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the breast cancer-free
survival (BCFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when
administered to patients with operable node-positive or high-risk node-negative
triple-negative breast cancer.
III. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the recurrence-free
interval (RFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when
administered to patients with operable node-positive or high-risk node-negative
triple-negative breast cancer.
IV. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel will improve the distant recurrence-free
interval (DRFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when
administered to patients with operable node-positive or high-risk node-negative
triple-negative breast cancer.
V. To determine the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel
administered concurrently with carboplatin compared to the toxicity of
doxorubicin/cyclophosphamide followed by paclitaxel alone.
VI. To determine if germline breast cancer (BRCA) status is associated with benefit in IDFS
or OS from the addition of carboplatin to an adjuvant chemotherapy regimen of
doxorubicin/cyclophosphamide followed by paclitaxel in patients with operable node-positive
or high-risk node-negative triple-negative breast cancer.
VII. To determine if the addition of carboplatin will improve the RFI among the homologous
recombination (HR) deficient patients as determined by the homologous recombination
deficiency (HRD) score.
VIII. To determine whether the efficacy of carboplatin on RFI in HR-deficient patients
differs from that in patients who are not HR-deficient.
IX. To collect tissue and blood samples at several occasions for future biomarkers
development in predicting risk of breast cancer recurrence in patients with operable
node-positive or high-risk node-negative triple-negative breast cancer treated with
doxorubicin/cyclophosphamide followed by paclitaxel with or without carboplatin and
predicting benefit from the addition of carboplatin among these patients.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (DOXORUBICIN HYDROCHLORIDE [A] CYCLOPHOSPHAMIDE [C]-->WEEKLY PACLITAXEL [WP]):
Patients receive doxorubicin hydrochloride intravenously (IV) over 15 minutes and
cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses
in the absence of disease progression or unacceptable toxicity. Patients then receive
paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the
absence of disease progression or unacceptable toxicity.
ARM II (AC-->WP + CARBOPLATIN): Patients receive doxorubicin hydrochloride and
cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1,
8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks
for 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 5 years and
then every 12 months for 5 years.
Inclusion Criteria:
- The patient must have signed and dated an institutional review board (IRB)-approved
consent form that conforms to federal and institutional guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- The tumor must be unilateral invasive adenocarcinoma of the breast on histologic
examination
- All of the following staging criteria (according to the 7th edition of the American
Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met:
- By pathologic evaluation, primary tumor must be pT1-3
- By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b,
pN1c), pN2a, pN2b, pN3a, or pN3b
- If pN0, tumor must be > 3.0 cm
- The tumor must have been determined to be human epidermal growth factor receptor 2
(HER2)-negative as follows:
- Immunohistochemistry (IHC) 0-1+; or
- IHC 2+ and in situ hybridization (ISH) non-amplified with a ratio of HER2 to
centromere enumerator probe 17 (CEP17) < 2.0, and if reported, average HER2 gene
copy number < 4 signals/cells; or
- ISH non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average
HER2 gene copy number < 4 signals/cells
- The tumor must have been determined to be estrogen receptor (ER)-and progesterone
receptor (PgR)-negative assessed by current American Society of Clinical Oncology
(ASCO)/College of American Pathologists (CAP) guidelines; patients with < 1% ER and
PgR staining by IHC are considered negative
- The patient must have undergone either a mastectomy (total, skin-sparing, or
nipple-sparing) or lumpectomy
- For patients who undergo lumpectomy, the margins of the resected specimen must be
histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as
determined by the local pathologist; if pathologic examination demonstrates tumor at
the line of resection, additional excisions may be performed to obtain clear margins;
if tumor is still present at the resected margin after re-excision(s), the patient
must undergo mastectomy to be eligible; (patients with margins positive for lobular
carcinoma in situ [LCIS] are eligible without additional resection)
- For patients who undergo mastectomy, the margins must be free of residual gross
tumor; (patients with microscopic positive margins are eligible as long as
post-mastectomy radiation therapy [RT] of the chest wall will be administered)
- The patient must have completed one of the procedures for evaluation of pathologic
nodal status listed below.
- Sentinel lymphadenectomy alone:
- If pathologic nodal staging based on sentinel lymphadenectomy is pN0 or
pN1b;
- If pathologic nodal staging based on sentinel lymphadenectomy is pN1mi or
pN1a and the patient has undergone breast conserving surgery (with planned
breast radiotherapy), the primary tumor must be T1 or T2 by pathologic
evaluation and the nodal involvement must be limited to 1 or 2 positive
nodes
- Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph
nodes if the sentinel node (SN) is positive; or
- Axillary lymphadenectomy with or without SN isolation procedure
- The interval between the last surgery for breast cancer (including re-excision of
margins) and randomization must be no more than 60 days
- Absolute neutrophil count (ANC) must be >= 1200/mm^3
- Platelet count must be >= 100,000/mm^3
- Hemoglobin must be >= 10 g/dL
- Total bilirubin must be =< upper limit of normal (ULN) for the laboratory (lab)
unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's
disease or similar syndrome involving slow conjugation of bilirubin
- Alkaline phosphatase must be =< 2.5 x ULN for the lab
- Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab
- Note: If alanine aminotransferase (ALT) is performed instead of AST (per
institution's standard practice), the ALT value must be =< 1.5 x ULN; if both
were performed, the AST must be =< 1.5 x ULN
- Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the
study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI],
positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to
randomization does not demonstrate metastatic disease and the requirements above are
met
- Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone
pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan
performed within 90 days prior to randomization does not demonstrate metastatic
disease
- Adequate renal function determined within 6 weeks prior to randomization defined as
the most recent serum creatinine =< ULN or measured or calculated creatinine
clearance > 60 mL/min
- Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days
prior to randomization; (LVEF assessment performed by 2-dimensional [D]
echocardiogram is preferred; however, multi gated acquisition [MUGA] scan may be
substituted based on institutional preferences;) the LVEF must be >= 50% regardless
of the cardiac imaging facility's lower limit of normal
Exclusion Criteria:
- T4 tumors including inflammatory breast cancer
- Definitive clinical or radiologic evidence of metastatic disease; required imaging
studies must have been performed within 90 days prior to randomization
- Synchronous or previous contralateral invasive breast cancer; (patients with
synchronous and/or previous contralateral DCIS or LCIS are eligible)
- Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS;
(patients with synchronous or previous ipsilateral LCIS are eligible)
- History of non-breast malignancies (except for in situ cancers treated only by local
excision and basal cell and squamous cell carcinomas of the skin) within 5 years
prior to randomization
- Previous therapy with anthracyclines or taxanes for any malignancy
- Chemotherapy administered for the currently diagnosed breast cancer prior to
randomization
- Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone
replacement therapy; patients are eligible if these medications are discontinued
prior to randomization
- Cardiac disease (history of and/or active disease) that would preclude the use of the
drugs included in the treatment regimens; this includes but is not confined to:
- Active cardiac disease
- Angina pectoris that requires the current use of anti-anginal medication;
- Ventricular arrhythmias except for benign premature ventricular
contractions;
- Supraventricular and nodal arrhythmias requiring a pacemaker or not
controlled with medication;
- Conduction abnormality requiring a pacemaker;
- Valvular disease with documented compromise in cardiac function; or
- Symptomatic pericarditis
- History of cardiac disease
- Myocardial infarction documented by elevated cardiac enzymes or persistent
regional wall abnormalities on assessment of left ventricle (LV) function;
- History of documented congestive heart failure (CHF); or
- Documented cardiomyopathy
- Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150
mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if
initiation or adjustment of BP medication lowers pressure to meet entry criteria)
- Active hepatitis B or hepatitis C with abnormal liver function tests
- Patients known to be human immunodeficiency virus (HIV) positive with a baseline
cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of
acquired immune deficiency syndrome (AIDS) indicator conditions
- Intrinsic lung disease resulting in dyspnea
- History of hospitalization in past 12 months for diabetic ketoacidosis (DKA) or
hyperosmolar hyperglycemic nonketotic syndrome (HHNS)
- Active infection or chronic infection requiring chronic suppressive antibiotics
- Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral
sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse
Events (CTCAE) version (v)4.0
- Conditions that would prohibit administration of corticosteroids
- Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day
methylprednisolone equivalent (excluding inhaled steroids)
- Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80
and Cremophor® EL
- Other non-malignant systemic disease that would preclude the patient from receiving
study treatment or would prevent required follow-up
- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements
- Pregnancy or lactation at the time of study entry; (note: pregnancy testing according
to institutional standards for women of childbearing potential must be performed
within 2 weeks prior to randomization)
- Use of any investigational product within 4 weeks prior to randomization
We found this trial at
970
sites
Baltimore, Maryland
Principal Investigator: Edward C. McCarron
Phone: 443-777-6311
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-7807
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Erica L. Mayer
Phone: 617-632-1930
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: John K. Erban
Phone: 617-636-7060
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-5351
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Ellis G. Levine
Phone: 716-845-8008
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-2278
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Avi B. Markowitz
Phone: 409-772-3533
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Julie R. Nangia
Phone: 713-798-1857
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: James T. Thigpen
Phone: 601-984-5689
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-954-2116
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-954-2116
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
701 Doctors Dr
Kinston, North Carolina 28504
Kinston, North Carolina 28504
(252) 559-2200
Principal Investigator: Peter R. Watson
Phone: 252-559-2200
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Issam Makhoul
Phone: 501-686-6342
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Harry D. Bear
Phone: 804-828-4808
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Virginia G. Kaklamani
Phone: 210-692-7502
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
34800 Bob Wilson Dr,
San Diego, California 92134
San Diego, California 92134
(619) 532-6400
Principal Investigator: Harvey B. Wilds
Phone: 619-532-8178
Naval Medical Center - San Diego We are the largest and most comprehensive military healthcare...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Abilene, Texas 79601
Principal Investigator: Christopher J. Trauth
Phone: 888-823-5923
Click here to add this to my saved trials
Abilene, Texas 79606
Principal Investigator: Michael V. Seiden
Phone: 281-298-8907
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-7438
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 419-479-5855
Click here to add this to my saved trials
Aiea, Hawaii 96701
Principal Investigator: Kenneth N. Sumida
Phone: 808-539-9337
Click here to add this to my saved trials
Aiea, Hawaii 96701
Principal Investigator: Kenneth N. Sumida
Phone: 808-539-9337
Click here to add this to my saved trials
1 Akron General Ave
Akron, Ohio 44307
Akron, Ohio 44307
(330) 344-6000
Principal Investigator: Esther H. Rehmus
Phone: 330-344-6348
Akron General Medical Center It
Click here to add this to my saved trials
Albany, Georgia 31701
Principal Investigator: Robert F. Krywicki
Phone: 229-312-2251
Click here to add this to my saved trials
Albemarle, North Carolina 28002
Principal Investigator: Geetha Vallabhaneni
Phone: 704-403-1520
Click here to add this to my saved trials
Alexandria, Louisiana 71301
Principal Investigator: John T. Cole
Phone: 504-842-4533
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Michael V. Seiden
Phone: 281-298-8907
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
American Fork, Utah 84003
Principal Investigator: Michelle H. Gilbert
Phone: 435-688-4901
Click here to add this to my saved trials
1111 Duff Ave
Ames, Iowa 50010
Ames, Iowa 50010
(866) 972-5477
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Jonathan A. Polikoff
Phone: 619-641-2838
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: John E. Doster
Phone: 864-512-4665
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Anne F. Schott
Phone: 734-936-4940
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-2278
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Hamied R. Rezazadeh
Phone: 715-847-2409
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Louis Fehrenbacher
Phone: 707-651-2792
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
Asheboro, North Carolina 27203
(336) 625-5151
Principal Investigator: Janak K. Choksi
Phone: 336-538-8029
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-418-1348
Click here to add this to my saved trials
Asheville, North Carolina 28816
Principal Investigator: Cameron B. Harkness
Phone: 828-418-1348
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-418-1348
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-4212
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Amelia B. Zelnak
Phone: 770-205-5291
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Stacy D. D'Andre
Phone: 916-453-3313
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Stacy D. D'Andre
Phone: 916-453-3313
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 907-458-5380
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-4212
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2642
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2642
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Kendrith M. Rowland
Phone: 217-383-3466
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Michael V. Seiden
Phone: 281-298-8907
Click here to add this to my saved trials
Austin, Texas 78701
Principal Investigator: Om N. Pandey
Phone: 512-324-3349
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Michael V. Seiden
Phone: 281-298-8907
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 907-458-5380
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Jonathan A. Polikoff
Phone: 619-641-2838
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 417-820-3587
Click here to add this to my saved trials
345 St Paul Pl
Baltimore, Maryland 21202
Baltimore, Maryland 21202
(410) 332-9000
Principal Investigator: David A. Riseberg
Phone: 410-951-7950
Mercy Medical Center "Mercy Medical Center" is a hospital located in Baltimore, Maryland. The landmark...
Click here to add this to my saved trials
Baltimore, Maryland 21244
Principal Investigator: Leon C. Hwang
Phone: 301-548-5743
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Kenneth D. Miller
Phone: 410-601-8448
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Edward C. McCarron
Phone: 443-777-6311
Click here to add this to my saved trials
Baltimore, Maryland 21239
Principal Investigator: Edward C. McCarron
Phone: 443-777-6311
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-7807
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 308-398-5351
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: Bridgette M. Collins-Burow
Phone: 504-988-2368
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Augusto C. Ochoa
Phone: 504-210-2970
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: Bridgette M. Collins-Burow
Phone: 504-988-2368
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Augusto C. Ochoa
Phone: 504-210-2970
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: John T. Cole
Phone: 504-842-4533
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Augusto C. Ochoa
Phone: 504-210-2970
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: Augusto C. Ochoa
Phone: 504-210-2970
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-954-2116
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Anjali S. Advani
Phone: 216-444-9464
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Shannon L. Puhalla
Phone: 412-641-2294
Click here to add this to my saved trials
Bedford, Texas 76022
Principal Investigator: Michael V. Seiden
Phone: 281-298-8907
Click here to add this to my saved trials
Bel Air, Maryland 21014
Principal Investigator: Ashkan Bahrani
Phone: 443-643-3011
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 907-458-5380
Click here to add this to my saved trials
Bellevue, Washington 98005
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Jonathan A. Polikoff
Phone: 619-641-2838
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: John P. Kuebler
Phone: 614-488-2745
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
1300 Anne Street NW
Bemidji, Minnesota 56601
Bemidji, Minnesota 56601
(218) 751-5430
Principal Investigator: Preston D. Steen
Phone: 701-234-6444
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Paul G. Montgomery
Phone: 208-381-3124
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Stacy D. D'Andre
Phone: 916-453-3313
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Marie E. Wood
Phone: 802-656-5493
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
Bettendorf, Iowa 52722
(563) 355-7733
Principal Investigator: Shobha R. Chitneni
Phone: 563-355-7733
Hematology Oncology Associates of the Quad Cities
Click here to add this to my saved trials
Bettendorf, Iowa 52722
Principal Investigator: David M. Spector
Phone: 309-779-4200
Click here to add this to my saved trials
Beverly, Massachusetts 01915
Principal Investigator: Angus P. McIntyre
Phone: 978-283-4000
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 406-237-5470
Click here to add this to my saved trials